Brief: Alector To Discontinue Phase 2 Trial Of Nivisnebart
29/04/2026 21:26
April 29 (Reuters) - Alector Inc ALEC.O: ALECTOR TO DISCONTINUE PHASE 2 PROGRESS-AD TRIAL OF NIVISNEBART (AL101/GSK4527226) IN EARLY ALZHEIMER’S DISEASE FOLLOWING INTERIM FUTILITY ANALYSIS ALECTOR INC - TARGETS IND APPLICATION FOR AL050 ENZYME REPLACEMENT THERAPY IN 2027 ALECTOR INC - TARGETS IND SUBMISSION FOR AL037/AL137 ANTI-AMYLOID BETA ANTIBODY IN Q1 2027 Source text: ID:nGNX1PZXT5 Further company coverage: ALEC.O ((Reuters.Briefs@thomsonreuters.com;))